Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS, Kim JA, Kim SW; Gemigliptin Study 006 Group. Rhee EJ, et al. Among authors: sosale ar. Diabetes Obes Metab. 2013 Jun;15(6):523-30. doi: 10.1111/dom.12060. Epub 2013 Jan 30. Diabetes Obes Metab. 2013. PMID: 23320436 Clinical Trial.
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
Yang SJ, Min KW, Gupta SK, Park JY, Shivane VK, Pitale SU, Agarwal PK, Sosale A, Gandhi P, Dharmalingam M, Mohan V, Mahesh U, Kim DM, Kim YS, Kim JA, Kim PK, Baik SH. Yang SJ, et al. Diabetes Obes Metab. 2013 May;15(5):410-6. doi: 10.1111/dom.12042. Epub 2012 Dec 17. Diabetes Obes Metab. 2013. PMID: 23170990 Clinical Trial.
A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.
Jung CH, Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS; Gemigliptin Study 006 Group. Jung CH, et al. Among authors: sosale ar. Diabetes Obes Metab. 2018 Jun;20(6):1535-1541. doi: 10.1111/dom.13256. Epub 2018 Apr 6. Diabetes Obes Metab. 2018. PMID: 29436761 Clinical Trial.
Prescribing Patterns and Response to Antihyperglycemic Agents Among Novel Clusters of Type 2 Diabetes in Asian Indians.
Anjana RM, Siddiqui MK, Jebarani S, Vignesh MA, Kamal Raj N, Unnikrishnan R, Pradeepa R, Panikar VK, Kesavadev J, Saboo B, Gupta S, Sosale AR, Seshadri KG, Deshpande N, Chawla M, Chawla P, Das S, Behera M, Chawla R, Nigam A, Gupta A, Kovil R, Joshi SR, Agarwal S, Bajaj S, Pearson ER, Doney ASF, Palmer CNA, Mohan V. Anjana RM, et al. Among authors: sosale ar. Diabetes Technol Ther. 2022 Mar;24(3):190-200. doi: 10.1089/dia.2021.0277. Epub 2022 Jan 5. Diabetes Technol Ther. 2022. PMID: 34609928
Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India: The INDEPENDENT Randomized Clinical Trial.
Ali MK, Chwastiak L, Poongothai S, Emmert-Fees KMF, Patel SA, Anjana RM, Sagar R, Shankar R, Sridhar GR, Kosuri M, Sosale AR, Sosale B, Rao D, Tandon N, Narayan KMV, Mohan V; INDEPENDENT Study Group. Ali MK, et al. Among authors: sosale ar. JAMA. 2020 Aug 18;324(7):651-662. doi: 10.1001/jama.2020.11747. JAMA. 2020. PMID: 32809002 Free PMC article. Clinical Trial.
The burden of diabetes and impaired fasting glucose in India using the ADA 1997 criteria: prevalence of diabetes in India study (PODIS).
Sadikot SM, Nigam A, Das S, Bajaj S, Zargar AH, Prasannakumar KM, Sosale A, Munichoodappa C, Seshiah V, Singh SK, Jamal A, Sai K, Sadasivrao Y, Murthy SS, Hazra DK, Jain S, Mukherjee S, Bandyopadhay S, Sinha NK, Mishra R, Dora M, Jena B, Patra P, Goenka K; DiabetesIndia. Sadikot SM, et al. Diabetes Res Clin Pract. 2004 Dec;66(3):293-300. doi: 10.1016/j.diabres.2004.04.007. Diabetes Res Clin Pract. 2004. PMID: 15536027
Comparing the ADA 1997 and the WHO 1999 criteria: Prevalence of Diabetes in India Study.
Sadikot SM, Nigam A, Das S, Bajaj S, Zargar AH, Prasannakumar KM, Sosale A, Munichoodappa C, Seshiah V, Singh SK, Jamal A, Sai K, Sadasivrao Y, Murthy SS, Hazra DK, Jain S, Mukherjee S, Bandyopadhay S, Sinha NK, Mishra R, Dora M, Jena B, Patra P, Goenka K; DiabetesIndia. Sadikot SM, et al. Diabetes Res Clin Pract. 2004 Dec;66(3):309-15. doi: 10.1016/j.diabres.2004.04.009. Diabetes Res Clin Pract. 2004. PMID: 15536028
The burden of diabetes and impaired glucose tolerance in India using the WHO 1999 criteria: prevalence of diabetes in India study (PODIS).
Sadikot SM, Nigam A, Das S, Bajaj S, Zargar AH, Prasannakumar KM, Sosale A, Munichoodappa C, Seshiah V, Singh SK, Jamal A, Sai K, Sadasivrao Y, Murthy SS, Hazra DK, Jain S, Mukherjee S, Bandyopadhay S, Sinha NK, Mishra R, Dora M, Jena B, Patra P, Goenka K; DiabetesIndia. Sadikot SM, et al. Diabetes Res Clin Pract. 2004 Dec;66(3):301-7. doi: 10.1016/j.diabres.2004.04.008. Diabetes Res Clin Pract. 2004. PMID: 15609460
27 results